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Background: Extensively drug-resistant (XDR) tuberculosis (TB) and HIV coinfection is associated with low cure
rates and high mortality. Clofazimine has shown activity in vitro against Mycobacterium tuberculosis, but clinical
experience with clofazimine in XDR-TB and HIV coinfection is limited.
Methods: This was a retrospective cohort study of adult XDR-TB patients in KwaZulu-Natal, South Africa, treated
with either a clofazimine- or non-clofazimine-containing XDR-TB treatment regimen. The primary outcome
measure was TB culture conversion at 6 months. Survival analysis and multivariate logistic regression compared
time to event in different strata and identified risk factors for TB culture conversion.
Results: Between August 2009 and July 2011, eligible XDR-TB patients (n¼85) were initiated on treatment for
XDR-TB. Most patients (86%) were HIV-infected and receiving antiretroviral therapy (90%). Patients receiving a
clofazimine-containing regimen (n¼50) had a higher percentage of culture conversion (40%) compared with
patients (n¼35) receiving a non-clofazimine regimen (28.6%). On multivariate analysis, there was a 2-fold
increase in TB culture conversion at 6 months (hazard rate ratio 2.54, 95% CI 0.99 –6.52, P¼0.05) in the
group receiving a clofazimine-containing regimen. Adverse effects due to clofazimine were minor and rarely
life-threatening.
Conclusions: Clofazimine was associated with improved culture conversion in the treatment of XDR-TB/HIV.
Adverse effects were minor and non-life-threatening. Based on these preliminary data, further study of clofazi-
mine in XDR-TB/HIV treatment is warranted. Given the present low rates of culture conversion in XDR-TB treat-
ment, we recommend empirical inclusion of clofazimine in treatment regimens for XDR-TB.
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Introduction
Increasing incidence of extensively drug-resistant (XDR) tubercu-
losis (TB)1 has created a need for more effective treatment regi-
mens,2 especially in XDR-TB/HIV-coinfected patients in whom
low cure and high mortality rates prevail.3,4
The protracted course of TB drug discovery has stimulated
repurposing existing drugs, such as clofazimine. Clofazimine
uniquely concentrates within macrophages, ideal for treating
slow-growing organisms,5,6 with demonstrated improved culture
conversion in murine models and success in shortening treatment
duration in a multidrug-resistant (MDR) TB case series.7,8
Clofazimine has been incorporated into treatment guidelines for
severe drug-resistant TB.9 An XDR-TB systematic review
demonstrated a treatment success rate of 66% with clofazimine-
containing regimens.10 However, published studies provide few
data supporting its use in XDR-TB/HIV coinfection.10 – 12
We performed a retrospective cohort study to evaluate the
effect of clofazimine-containing regimens on culture conversion
in XDR-TB/HIV coinfection.
Methods
We reviewed the case records of patients ≥18 years with microbiologically
confirmed XDR-TB, admitted to a specialist TB hospital in KwaZulu-Natal,
South Africa, between August 2009 and July 2011. Patients were excluded
if they had a history of XDR-TB treatment, clofazimine added to their regi-
men subsequent to treatment initiation or unavailable TB culture results.
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Antimycobacterial treatment regimens, including clofazimine, were
determined by treating physicians based on clinical judgement, suscepti-
bility results and safety parameters.
Eligible patients were stratified into two treatment groups: those trea-
ted with a clofazimine-containing regimen (clofazimine group) and those
treated without clofazimine (non-clofazimine group). Treatment regimens
were tailored to the isolate’s susceptibility. The clofazimine dosage used
was either 200 or 300 mg daily based on weight,13 with regimen change
due to clofazimine-related adverse events noted.
Data collection
A standardized data extraction form was used. The variables collected are
presented in Tables 1 and 2 and were obtained as part of standard clin-
ical care.
Culture and drug susceptibility testing (DST)
Mycobacterium tuberculosis was cultured using BACTEC MGIT 960 (Becton
Dickinson, Sparks, MD, USA) and 7H11 Middlebrook medium with DST by
the 1% proportion method.14
Outcome, definitions and follow-up
Standard treatment outcome definitions as per Laserson et al.15 were
used. The primary outcome was time to culture conversion, which was
defined as the time from treatment initiation to the date of the first of
two consecutive negative cultures ≥1 month apart. Sputum outcomes
were measured up to 12 months.
Statistical analysis
Comparisons between patients in both groups were performed using
either Fisher’s exact test (categorical data) or the Wilcoxon rank sums
test (continuous data). Patients who did not culture convert were censored
at their last follow-up visit (recorded by sputum collection dates). For the
6 month culture conversion analysis, time to conversion was censored at
6 months. Proportional hazards regression analyses were performed to
assess factors associated with 6 month culture conversion.
Ethics approval
The study was approved by the Albert Einstein College of Medicine and the
University of KwaZulu-Natal.
Results
During August 2009 to July 2011, 204 patients were admitted for
XDR-TB treatment with culture-confirmed XDR-TB at baseline.
Eighty-five patients met the inclusion criteria; 50 newly diagnosed
with XDR-TB were treated with clofazimine (‘clofazimine group’)
and 35 patients were treated with a non-clofazimine-containing
regimen (‘non-clofazimine group’). The remaining 119 patients
were excluded: pre-XDR-TB (n¼18); history of XDR-TB treatment
(n¼30) (excluded due to pre-exposure to study drugs); no
M. tuberculosis culture (n¼16); and clofazimine added to
XDR-TB treatment (n¼55).
Both groups were similar for baseline characteristics (Table 1).
Patients were followed for a maximum of 12 months after
XDR-TB treatment initiation (median follow-up 7.7 months, IQR
5.3–11.8). Thirty of 85 patients (35.3%) culture converted. Median
time to culture conversion was 13.5 weeks (IQR 8.9–20.4). In the
clofazimine group, 20/50 (40%) patients culture converted and in
the non-clofazimine group, 10/35 (28.6%) culture converted
(P¼0.05). Median time to culture conversion was 16.4 weeks
(IQR 9.0 –24.7) in the clofazimine group and 11.9 weeks (IQR
Table 1. Demographic and baseline characteristics of patients with XDR-TB treated with and without a clofazimine-containing regimen
Baseline characteristic Overall (n¼85) Clofazimine group (n¼50) Non-clofazimine group (n¼35) P
Age (years), median (IQR) 34 (26–42) 34 (26–40) 36 (26–43) 0.79
Female, n (%) 55 (64.7) 34 (68.0) 21 (60.0) 0.49
HIV+, n (%) 73 (85.9) 44 (88.0) 29 (82.9) 0.54
On ARVa in HIV+, n (%) 64/71 (90.1) 41/44 (93.2) 23/27 (85.2) 0.41
Baseline CD4 count (cells/mL)b, median (IQR) 221 (140–362) 185 (133–325) 250 (161–431) 0.22
Number of TB drugsc, median (IQR) 8 (7–9) 8 (7–9) 7 (7–9) 0.09
Drugs usedc, n (%)
pyrazinamide 83 (100) 49 (100) 34 (100) 1.00
capreomycin 82 (98.8) 48 (98.0) 34 (100) 1.00
ethionamide 82 (98.8) 49 (100) 33 (97.1) 0.41
moxifloxacin 82 (98.8) 48 (98.0) 34 (100) 1.00
para-aminosalicylic acid 79 (95.2) 46 (93.9) 33 (97.1) 0.64
terizidone 75 (90.4) 44 (89.8) 31 (91.2) 1.00
ethambutol 74 (89.2) 43 (87.8) 31 (91.2) 0.73
isoniazid 43 (51.8) 32 (65.3) 11 (32.4) ,0.01
amoxicillin/clavulanate 41 (49.4) 29 (59.2) 12 (35.3) 0.04
clarithromycin 26 (31.0) 15 (30.6) 11 (31.4) 1.00
rifampicin 2 (2.4) 0 (0.0) 2 (5.9) 0.16
ofloxacin 1 (1.2) 0 (0.0) 1 (2.9) 0.41
aTwo patients did not have ARV status available.
bBaseline CD4 cells/mL data available for 58 patients only.













8.6– 18.4) in the non-clofazimine group (P¼0.37). In the first
2 months of treatment, there was no difference in the probability
of culture conversion between groups. After 2 months, the prob-
ability of culture conversion was higher in the clofazimine group
(Figure 1). By month 4, 32% of patients in the clofazimine group
and 16% in the non-clofazimine group culture converted. In both
groups, most culture conversions occurred within the first
6 months. In the clofazimine group, 18/20 culture conversions
occurred before 6 months, while the remaining 2 converted
before 12 months. Similarly, in the non-clofazimine group, 8/10
culture conversions occurred before 6 months and the remaining
2 before 12 months. Patients in the clofazimine group were twice
as likely to culture convert within 6 months after XDR-TB treat-
ment initiation. Year of starting XDR-TB treatment also had an
impact on culture conversion. HIV status, antiretroviral (ARV),
sex and age did not affect 6 month culture conversion (Table 2).
Baseline chest radiograph (CXR) score was not associated with
Table 2. Predictors of 6 month culture conversion in XDR-TB in the clofazimine- and non-clofazimine groups
Variable
Number converted
within 6 months (%)
Unadjusted hazard
rate ratio (95% CI) P
Adjusted hazard
rate ratio (95% CI) P
All patients
age (per 10 year increase) 0.94 (0.63–1.39) 0.76
gender
female 17 (30.9) 1.00 (reference)
male 9 (30.0) 0.92 (0.41–2.07) 0.84
HIV status
negative 3 (25.0) 1.00 (reference) 1.00 (reference)
positive 23 (31.5) 1.23 (0.37–4.09) 0.74 1.10 (0.33–3.69) 0.88
baseline CD4 count (per 50 cells/mL increase) 1.01 (0.91–1.13) 0.83
year initiated treatment
2011 11 (27.5) 1.00 (reference) 1.00 (reference)
2009 and 2010 15 (33.3) 1.27 (0.58–2.76) 0.55 2.02 (0.85–4.88) 0.11
clofazimine-containing group
no 8 (22.9) 1.00 (reference) 1.00 (reference)
yes 18 (36.0) 1.75 (0.76–4.02) 0.19 2.54 (0.99–6.52) 0.05
baseline CXR scorea (per 10 unit decrease) 1.03 (0.91–1.17) 0.62
change in CXR score from baseline to 6 monthsa
(per 10 unit decrease)
1.46 (1.08–1.98) 0.02
HIV-infected patients only
age (per 10 year increase) 0.81 (0.50–1.33) 0.41
gender
female 15 (30.6) 1.00 (reference)
male 8 (33.3) 1.04 (0.44–2.45) 0.93
ARV status
on ARVs 21 (32.8) 1.00 (reference) 1.00 (reference)
not on ARVs 2 (28.6) 0.87 (0.21–3.73) 0.86 0.79 (0.18–3.43) 0.75
baseline CD4 count (per 50 cells/mL increase) 1.01 (0.91–1.13) 0.83
year initiated treatment
2011 8 (23.5) 1.00 (reference) 1.00 (reference)
2009 and 2010 15 (38.5) 1.85 (0.78–4.36) 0.16 2.72 (1.03–7.14) 0.04
clofazimine-containing group
no 8 (27.6) 1.00 (reference) 1.00 (reference)
yes 15 (34.1) 1.31 (0.55–3.08) 0.54 2.02 (0.77–5.30) 0.15
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Figure 1. Cumulative incidence estimates of XDR-TB culture conversion in
the clofazimine and non-clofazimine groups.













6 month culture conversion; however, change in CXR score by
6 months was statistically significant (Table 2).16
Among XDR-TB/HIV-coinfected patients, none of the baseline
characteristics (Table 1) was associated with TB culture conver-
sion at 6 months. Clofazimine showed a similar magnitude of
effect as in the overall group, but this was not statistically signifi-
cant. However, in the adjusted analysis, year of treatment initi-
ation was significantly associated with culture conversion
(Table 2). During 2009–11, the median number of TB medications
patients received increased (P¼0.02) as well as the proportion ini-
tiating ARVs (trend P¼0.04).
Data regarding adverse reactions were available in 42/50
patients in the clofazimine group. Most patients (32/42) did not
experience a clofazimine-related adverse reaction: 6 patients
(14%) had a skin reaction; 3 (7%) had mild nausea and diarrhoea;
and 1 became confused (2%). Clofazimine was discontinued in
3/10 patients due to severe vomiting (n¼1), confusion (n¼1)
and skin discoloration (n¼1). Most patients with adverse events
were HIV infected.
Overall, 43.5% (37/85) died or were lost to follow-up and only
12.9% (11/85) were cured or completed treatment. There was no
significant difference between the proportion of deaths in the clo-
fazimine group versus the non-clofazimine group [36.0% (18/50)
versus 54.3% (19/35), P¼0.1212]. In the clofazimine group,
58.0% (29/50) were lost to follow-up and at the last visit, 50%
(14/28) were still culture positive (median time of 7 months,
range 3–15 months).
Discussion
We demonstrated that XDR-TB patients, the majority coinfected
with HIV, are more than twice as likely to culture convert (hazard
rate ratio 2.54, 95% CI 0.99–6.52, P¼0.05) when treated with a
clofazimine-containing regimen compared with patients treated
with non-clofazimine-containing regimens in the same setting.
Whilst few studies describe the effect of clofazimine in XDR-TB,
even fewer report XDR-TB with HIV coinfection. In a long-term
study of XDR-TB treatment elsewhere in South Africa, with lower
HIV prevalence, clofazimine was an independent predictor of culture
conversion.4 Similar benefits were seen in HIV-uninfected patients in
Shanghai and Bangladesh, with low treatment failure.7,17
The culture conversion rate in the clofazimine group was 40%
compared with 28.6% in the non-clofazimine group (P¼0.05).
Although higher than the 20% culture conversion rates previously
described,18 it was lower than the 56.4% achieved in non-HIV set-
tings.17 In Bangladesh, the treatment of MDR-TB showed
clofazimine-containing regimens were the most effective, with
cure rates as high as 84.2% in an HIV-uninfected cohort.7
Time to culture conversion was shorter in the non-clofazimine
group compared with the clofazimine group, although not statis-
tically significant. In the first 2 months, there was no difference in
culture conversion between the groups. After 2 months, the prob-
ability of culture conversion was higher in the clofazimine group.
In both groups, most of the culture conversions occurred within
the first 6 months. The delayed contribution of clofazimine may
result from extensive binding and time required to accumulate
in tissues, to reach binding saturation and then permit release
of microbiologically active free drug. In addition, its ability to con-
centrate in macrophages and long half-life may result in sus-
tained efficacy synergistic with pyrazinamide.19
Consistent with data from uncontrolled studies, HIV status,
ARV and CD4 count did not affect M. tuberculosis culture conver-
sion at 6 months.3 Although there has been some suggestion of
worse outcome with clofazimine in HIV-coinfected patients with
XDR-TB,4 this was not seen in our study. Our study demonstrates
that clofazimine as part of a background treatment regimen
improves M. tuberculosis culture conversion and has the potential
to improve treatment outcomes in XDR-TB/HIV-coinfected
patients. Early initiation of ART in MDR-TB patients has been
shown to reduce mortality by 86%.20 Integrated XDR-TB and
HIV treatment will likely improve outcomes in dually infected
patients. The limited data on radiological improvement may
serve as a surrogate marker of culture conversion.
The optimal dose of clofazimine has not been defined. In this
study, patients received either 200 or 300 mg of clofazimine
daily,13 higher than in other studies.7,17 Few adverse events
were reported even in HIV-infected patients, most of whom
were also receiving an ARV, but these were minor with low treat-
ment stoppages, similar to published reports.11
Our study has several limitations. The decision to initiate
clofazimine treatment was made by the individual treating phys-
ician with no uniform criteria, thus selection bias may exist.
Clofazimine susceptibility testing was unavailable. The review was
limited to 12 months and the improved rates of culture conversion
may not translate to improved cure at 24 months. Significant attri-
tion in this cohort restricts inferences of final outcome.
The small sample and the retrospective analysis limit our study
conclusion. Clofazimine was used as part of an individualized
treatment regimen including on average six other medications,
so outcomes cannot be definitively ascribed to clofazimine.
Despite these limitations, our study adds important knowledge
on the subject of clofazimine for the treatment of XDR-TB in a
largely HIV-infected cohort, demonstrating improved culture con-
version with minor adverse events.
In the absence of new drugs and effective treatment options,
repurposing clofazimine as an additional drug for XDR-TB treat-
ment increases therapeutic options, even in high HIV prevalence
settings. Due to the paucity of clinical efficacy of clofazimine-
containing regimens, the authors suggest the need for a con-
trolled clinical trial.
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